Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

rscheringpharma.de .

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the initiation of clinical trials, regulatory plans and expected timelines for alemtuzumab, including the initiation of a second Phase 3 trial in MS patients and the timing thereof, the timing of obtaining clinical trial data, enrollment in clinical trials and the ability to manage patient safety. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: that final results of the clinical trial demonstrate safety and efficacy comparable to the interim data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements

Genzyme(R), Campath(R), and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved. Rebif(R) is a registered trademark of EMD Serono, Inc.<
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Perrigo Company plc ("Perrigo") (NYSE: ... Affordable Healthcare Products®," today announced the closing of Perrigo,s ... of 6,809,210 ordinary shares at a public offering price ... the option to purchase up to an additional 888,157 ... Capital Inc., as representatives of the several underwriters. ...
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... CUMBERLAND, Md. , Nov. 26, 2014  Over ... half of those suffer from this pain daily. Chronic ... specialty of pain management is born to fulfill the ... treat all types of pain. On October ... to the Cumberland, Maryland community.  ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
(Date:11/28/2014)... NY (PRWEB) November 28, 2014 Junk-A-Car ... companies, is expanding their service offerings to help drivers, ... City, Philadelphia and Washington, D.C. metropolitan areas deal with ... sweep across a large part of the country. , ... areas resulting in hundreds of totaled, crashed and ...
(Date:11/28/2014)... Mequon, Wisconsin (PRWEB) November 28, 2014 ... facial plastic surgeons , announced the expansion of Quintessa ... new center will be located at W307 N1497 Golf ... 2015. , According to Dr. Campbell, the new Delafield ... non-surgical procedures for patients, including: Botox, filler ...
(Date:11/28/2014)... 28, 2014 Secura Consultants, based ... insurance marketing organizations in the country focused on ... protection marketplace. Secura Consultants is proud to offer ... Financial Group, a leading global financial company. , ... With the ownership interest comes the need for ...
(Date:11/28/2014)... November 28, 2014 Not only is ... products free of petroleum, parabens and other cancer-causing agents, ... fund research, education and awareness programs that help in ... and owners have raised an incredible, record-breaking contribution of ... Cure, sales of the Sweet Red Rose Whip Moisturizer ...
(Date:11/28/2014)... 2014 More than 2,100 Stryker ... filed in a New Jersey litigation that involves ... LLP reports. , A Case List updated ... reflects the filing of 2,160 claims over the ... were voluntarily recalled on July 6, 2012 by ...
Breaking Medicine News(10 mins):Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... of Health Insurance Convention Expected to Draw ... Thousands of Protestors to San Francisco,Delgadillo to Discuss Legal Efforts to ... and Unfair Business Acts and Practices" of Insurers, ... national day of,protest against health insurance corporations, Los Angeles City Attorney,Rocky ...
... the team that made the discovery, Professor Christopher Rowe ... and treatment presents medical practitioners with the best opportunity ... is at an experimental stage, this work places Australia ... Rowe says. , A 2004 Access Economics report calculated ...
... lane 1? , Researchers at the University of Alberta ... time are reporting findings that may have sprinters thinking twice ... by Dave Collins, professor of physical education and recreation, and ... at the Olympic Games would allow racers closer to the ...
... Hosts, Live Call-ins, Interactive Blogs on Topics From Holistic Health ... ... BOCA RATON, Fla., June 18 BocaRaton.com and The Bites!,Network ... called "The Insight" featuring three hosts who will,discuss various topics ...
... Calif., June 18 Nuvelo, Inc.,(Nasdaq: NUVO ) ... chairman,and chief executive officer, will present at the Jefferies ... 1:30 p.m. ET in New,York City., A live ... via,the Investor Relations portion of Nuvelo,s website at ...
... SUNNYVALE, Calif., June 18 Accuray,Incorporated (Nasdaq: ARAY ... today that its president and chief executive officer, Euan ... Healthcare,Conference on Thursday, June 26, 2008 at 10:15 a.m. ... the presentation will be available online from the,investor relations ...
Cached Medicine News:Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 2Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 3Health News:Advance towards early Alzheimer's diagnosis 2Health News:Sprinters closest to starter pistol have advantage over those farther away, says study 2Health News:A South Florida Premiere 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: